Prosecution Insights
Last updated: August 16, 2026
Application No. 18/927,285

SILICON PRECURSOR COMPOUND AND PREPARATION METHOD THEREFOR, AND SILICON-CONTAINING THIN FILM PREPARATION METHOD USING SILICON PRECURSOR

Non-Final OA §103
Filed
Oct 25, 2024
Priority
Apr 25, 2022 — RE 10-2022-0050831 +1 more
Examiner
BAKSHI, PANCHAM
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Merck Patent GmbH
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
895 granted / 1162 resolved
+17.0% vs TC avg
Strong +30% interview lift
Without
With
+30.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
75 currently pending
Career history
1227
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
30.4%
-9.6% vs TC avg
§102
19.9%
-20.1% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1162 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 07/20/2026 has been entered. Status of the Application Applicant’s IDS, filed on 07/20/2026 is acknowledged. In view of IDS, allowance is hereby withdrawn and restriction is maintained. Claims 1-19 are pending, of which claims 3-19 are withdrawn. Claims 1-2 are under current examination. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-2 are rejected under 35 U.S.C. 103 as being unpatentable over Xinjian (US20220178028 A1), and KLINGEBIEL ("Aminofluorosilanes: Formation of heterocycles and lithio-aminofluorosilanes", Journal of Natural Research B, Retrieved from the Internet: "URL: https://www.degruyterbrill.com/document/doi/10.1515/znb-1977-0511/ pdf", January 01, 1977, pp. 537-542; as provided by the applicant on IDs dated 07/20/2026) in combination. Determining the scope and contents of the prior art Xinjian, teaches compound of formula: PNG media_image1.png 217 593 media_image1.png Greyscale for making thin films (entire application). which differs from the instant claims with respect to X substituent as CH3 vs H or halogen of the instant claims. KLINGEBIEL teaches several compounds and derivatives, such as: PNG media_image2.png 346 879 media_image2.png Greyscale see compounds 1-12, wherein Si sandwiched between two N atoms is substituted with halogens, or halogen and alkyl (entire article, especially page 537). Ascertaining the differences between the prior art and the claims at issue Xinjian, teaches compound of formula: PNG media_image1.png 217 593 media_image1.png Greyscale , which differs from the instant claims with respect to X substituent on Si sandwiched between two N as CH3 vs H or halogen of the instant claims. KLINGEBIEL teaches several compounds and derivatives, such as: PNG media_image2.png 346 879 media_image2.png Greyscale see compounds 1-12, wherein Si sandwiched between two N atoms is substituted with halogens, or halogen and alkyl, but fails to teach same compound as in the instant claims having same substituents on N and Si. Resolving the level of ordinary skill in the pertinent art With regards to the above difference- Since Xinjian, teaches compound of formula: PNG media_image1.png 217 593 media_image1.png Greyscale , which differs only with respect to X substituent on Si sandwiched between two N as CH3 vs H or halogen of the instant claims and KLINGEBIEL teaches several compounds and derivatives similar to compounds of the instant claims, wherein Si sandwiched between two N atoms is substituted with halogens, or halogen and alkyl and variation of substituents on N, such as alkyl, hydrogen and aryl, it would have been prima facie obvious to a person of ordinary skill in the art that that alkyl of Si sandwiched between two N of Xinjian’s compounds may be substituted with halogen as taught by KLINGEBIEL. Further, substitution of a methyl for a hydrogen is considered to be prima facie obvious. In re Woods 199 USPQ 137; further, homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). Based on the above established facts, it appears that the combination of teachings of above cited prior art read applicants’ compound. Therefore, all the claimed elements were known in the prior art and one skilled person in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Considering objective evidence present in the application indicating obviousness or nonobviousness To establish a prima facie case of obviousness, three basic criteria must be met: (1) the prior art reference must teach or suggest all the claim limitations; (2) there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings; and (3) there must be a reasonable expectation of success; and (MPEP § 2143). In this case, Xinjian, teaches compound of formula: PNG media_image1.png 217 593 media_image1.png Greyscale , and KLINGEBIEL teaches several compounds and derivatives, such as: PNG media_image2.png 346 879 media_image2.png Greyscale . So, the combination of prior art read applicants claims. In KSR International Vo. V. Teleflex Inc., 82 USPQ2d (U.S. 2007), the Supreme Court particularly emphasized “the need for caution in granting a patent based on a combination of elements found in the prior art,” (Id. At 1395) and discussed circumstances in which a patent might be determined to be obvious. Importantly, the Supreme Court reaffirmed principles based on its precedent that “[t]he combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results.” (Id. At 1395). See MPEP 2143 - Examples of Basic Requirements of a Prima Facie Case of Obviousness [R-9]. In this case at least prong (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success would apply. The rationale to support a conclusion that the claim would have been obvious is that “a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely that product [was] not of innovation but of ordinary skill and common sense. In that instance the fact that a combination was obvious to try might show that it was obvious under § 103.”KSR, 550 U.S. at ___, 82 USPQ2d at 1397. If any of these findings cannot be made, then this rationale cannot be used to support a conclusion that the claim would have been obvious to one of ordinary skill in the art. Further, there is a reasonable expectation of success that compounds with Si sandwiched between two N may be substituted with alkyls; alkyl and H; alkyl and halogen and can be made by combination of the above cited prior art. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention by taking the advantage of the teaching of the above cited references and to make the instantly claimed compound with a reasonable expectation of success. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached at 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Oct 25, 2024
Application Filed
Feb 03, 2026
Response after Non-Final Action
Jul 20, 2026
Request for Continued Examination
Jul 21, 2026
Response after Non-Final Action
Jul 30, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702712
ENTEROENDOCRINE CELL-TARGETING POLYMER SUBSTANCE CONJUGATED WITH PHOTOSENSITIZER, AND MEDICAL USE THEREOF FOR AMELIORATING METABOLIC DISEASE
3y 8m to grant Granted Aug 11, 2026
Patent 12697349
COMPOSITIONS AND METHODS FOR TREATING RAS-MUTANT CANCERS
4y 9m to grant Granted Aug 04, 2026
Patent 12698300
RUTHENIUM COMPLEX, PRODUCTION METHOD OF THE COMPLEX, AND PRODUCTION METHOD OF OPTICALLY ACTIVE SECONDARY ALCOHOLS USING THE COMPLEX AS CATALYST
3y 3m to grant Granted Aug 04, 2026
Patent 12673127
LIQUID EMBOLIC MATERIAL COMPOSITION
4y 1m to grant Granted Jul 07, 2026
Patent 12673965
RAW MATERIAL FOR CHEMICAL DEPOSITION CONTAINING ORGANORUTHENIUM COMPOUND, AND CHEMICAL DEPOSITION METHOD USING THE RAW MATERIAL FOR CHEMICAL DEPOSITION
3y 11m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.2%)
2y 3m (~5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1162 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month